Andrew L. Feldman, MD (Damon Runyon Clinical Investigator ‘09-‘14), and colleagues at the Mayo Clinic, Rochester, reported that novel genetic tests can be used to determine the best treatment options for patients with anaplastic large-cell lymphoma (ALCL), a rare type of non-Hodgkin lymphoma. There are three subgroups of ALCL that have very different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of the genetic tests, which the researchers recommend giving to all patients with ALK-negative ALCL. Each patient’s treatment should then be tailored based on the subgroup of his/her disease. The study was published in the journal Blood.